Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

- PMLiVE

NIH trial of AZ’s long-acting COVID-19 antibody launches in the US

Study will evaluate efficacy of drug in patients hospitalised with COVID-19

- PMLiVE

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses

- PMLiVE

South Africa puts AZ/Oxford COVID-19 vaccine roll-out on hold

Pre-print study results found jab offers 'minimal' protection against B.1.351 variant

- PMLiVE

FDA approves BMS’ blood cancer CAR T therapy after delay

The FDA's approval of Breyanzi came a year after the start of the review

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

EU may restrict exports of some COVID-19 vaccines

Proposed strategy follows a confrontation between the EU and AstraZeneca

- PMLiVE

The UK reasserts that the AZ vaccine is ‘effective across all age groups’

Germany's draft guidance does not recommend the vaccine for people over 65

- PMLiVE

AZ and EU fail to solve COVID-19 vaccine delivery issues

AZ temporarily reduced Q1 deliveries to the EU last week

- PMLiVE

AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

German media reports suggested vaccine is less than 10% effective in the elderly

- PMLiVE

BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma

- PMLiVE

AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU

Deliveries in the first quarter have been cut by 60%

- PMLiVE

BMS aims for US approval of Opdivo combo in stomach cancer

US regulator has set a goal date for a decision on 25 May

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links